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Replication-incompetent viruses have been extensively evaluated
as vectors for potential gene delivery to tumour cells, with signifi-
cant preclinical efficacy having been demonstrated by direct injec-
tion of localized tumour masses in animal models (Clayman et al,
1995; Arai et al, 1997; Sanding et al, 1997). However, a major
limitation is their apparent inability to effectively treat tumour
metastases (Roth and Cristiano, 1997). Selectively replication-
competent or oncolytic viruses hold promise for the treatment of a
variety of cancers. A simple protocol would involve the virus
being administered intravenously, potentially exposing many cells
to infection. However, the virus would only replicate in (and selec-
tively destroy) malignant cells. Such a procedure would be ideal
for the treatment of disseminated disease, the most commonly fatal
form of cancer, and would not require the physical targeting of
the agent. ONYX-015, for example, is an E1B gene-deleted
adenovirus which selectively replicates in and lyses cancer cells
expressing mutant p53 (Bischoff, 1996; Heise et al, 1997). This
virus has recently shown antitumoural efficacy in one model of
metastatic cancer (Heise et al, 1999).
The herpesviruses, primarily herpes simplex virus type 1
(HSV-1), are also under investigation as a potential source of
oncolytic viruses (Rampling et al, 1998). We are currently
developing gene therapy vectors based on herpesvirus saimiri
(HVS). The natural host of this virus is the squirrel monkey
(Saimiri sciureus) where it is able to persist without causing any
obvious disease. However, if the virus is experimentally trans-
mitted to other New World primates, the animals can develop
a number of lymphoproliferative diseases (Fleckenstein and
Desrosiers, 1982). HVS strains have been assigned to three
subgroups A, B and C, depending on their transforming and path-
ogenic capabilities and sequence divergence of a terminal region
of the viral L-DNA (Medveczky et al, 1984; 1989). In addition,
viruses from subgroup C have been shown to be capable of trans-
forming human T-cells in vitro (Beisinger et al, 1992). For reasons
of safety, we have therefore evaluated the A-strain of the virus,
which is incapable of transforming human T-cells. The virus has
been further modified by the removal of the saimiri transforming
protein (stpA), rendering it non-pathogenic and non-transforming
in all systems tested to date (Desrosiers et al, 1984; 1985; 1986;
Koomey et al, 1984).
It has been demonstrated that a selectable HVS genome has the
ability to persist episomally in a wide variety of human cell lines
for long periods of time, apparently without the production of
infectious progeny viruses in many cases (Grassman and
Fleckenstein, 1989; Simmer et al, 1991; Stevenson et al, 1999). In
this report, we demonstrate that HVS is selectively cytopathic in
pancreatic cancer cell lines, suggesting that it may have potential
as a specific oncolytic agent for pancreatic cancer.
MATERIALS AND METHODS
Cell culture
SW480 and HCT116 cells were routinely grown in RPMI 1640
and McCoy’s 5A media, respectively, supplemented with 10%
fetal calf serum (FCS) and the antibiotics penicillin and strepto-
mycin. PANC-1 and MIAPACA cells were routinely grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FCS and the antibiotics penicillin and streptomycin. All
tissue culture reagents were obtained from Gibco BRL (Paisley,
Scotland). SW480, MIAPACA and PANC-1 cells have a mutation
in the p53 gene, in contrast to HCT116 which possess the endoge-
nous wt-p53 gene (Nigro et al, 1989; Redston et al, 1994).
Virus
The marker virus HVS-GFP, containing the enhanced green fluo-
rescent protein (EGFP) and the neomycin resistance gene (NeoR),
has been described previously (Whitehouse and Stevenson, 1999).
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doi: 10.1054/ bjoc.2000.1346, available online at http://www.idealibrary.com on Briefly, it contains the EGFP gene under the control of a CMVIE
promoter and the NeoR gene under the control of an SV40
promoter, cloned between unique repetitive elements of the HVS
genome. The addition of these heterologous genes into the HVS
genome has no detectable effect on the growth of HVS-GFP in
comparison with the wild type virus.
Infection of cells
1 ´ 106 cells were infected at a multiplicity of infection (MOI) of 1
with extracellular stocks of HVS-GFP. Infections were carried out
in six-welled dishes by aspirating the culture medium and adding
the appropriate amount of virus in 0.5 ml of medium. The cells
were then incubated at 37°C for 90 min after which a further
1.5 ml of medium was added. Cultures were examined daily for
cytopathic effects (CPE).
Drugs
Acyclovir (ACV) (Sigma, Poole, UK) was dissolved in sterile water
and added to the tissue culture medium after infection with the virus.
Concentrations of between 0 and 100 mM were investigated.
Virus recovery assays
Supernatant was harvested and replaced, in infected cultures at 2,
5 and 7 days post-infection. 0.5 ml of each sample was used to
infect cultures of owl-monkey kidney (OMK) cells, in which HVS
is capable of forming plaques. The cultures were examined after
72 h by fluorescence microscopy for the presence of clusters of
green cells (indicative of the early stages of plaque formation).
This method of enumeration was possible because of the EGFP
expressed by the recombinant virus. Numbers of plaques were
confirmed by conventional visualization after 1 week.
RESULTS
Cytopathic effects in cell cultures
Examination of cells at 48 h post-infection showed significant
cytopathic effects in cultures of pancreatic cancer cells
(MIAPACA and PANC-1). This was in marked contrast to the
colonic cancer cells (SW480 and HCT116) which exhibited no
obvious CPE. Fluorescence microscopy revealed that, in all cases,
the vast majority of cells had been successfully infected by the
virus (i.e. exhibited a green phenotype) (Figure 1).
Extended analysis revealed that the CPE in the PANC-1 culture
was progressive, leading to the total destruction of the culture at 7
days post-infection (Figure 2). Although a similar CPE was noted
in the MIAPACA culture a few cells seemed to escape the effect,
allowing the monolayer to recover over time. The fact that these
cells were green indicated that they had been successfully infected,
though not destroyed, by the virus. At no time was any CPE noted
in cultures of SW480 and HCT116 cells. This result is consistent
with data from other colorectal lines including HT29s, the lung
carcinoma cell line A549s (data not shown) and the published
results on infection of other human cell lines (Simmer et al, 1991;
Stevenson et al, 1999).
The addition of ACV to infected and control cultures of
MIAPACA, SW480 and HCT116 had no apparent effect, whereas
in the case of infected PANC-1 cultures, increasing concentrations
appeared to accelerate the process of monolayer destruction (data
not shown).
Virus recovery assay
The results of the virus recovery assay are shown in Figure 3. High
numbers of green foci were produced in the OMK monolayers by
all of the 2-day infected culture supernatants. However, this was
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Figure 1 Microscopic analysis of pancreatic (PANC-1 and MIAPACA) and colorectal (HCT116 and SW480) cell lines at 48 h post-infection (A) mock-infected
cells at 48 h post-infection (B) 48 h post-infection with HVS-GFP at an MOI of 1 using bright field microscopy (C) 48 h post-infection with HVS-GFP at an MOI of
1 using FITC illuminationalso found with the 2-day sample from a control experiment in which
medium containing virus was incubated in the absence of cells.
At 5 days post-infection, MIAPACA and SW480 cells produced
the largest amounts of virus. In the absence of ACV, 60 green
forming units (gfu) per ml were present in the MIAPACA culture.
The presence of increasing concentrations of the drug reduced this
figure to 18 gfu ml–1. 20 gfu ml–1 were found in the SW480 culture
at the highest concentration (100 mM) of ACV, representing a less
significant reduction overall. Lower numbers of gfu ml–1 were
detected in the PANC-1 culture and minimal virus was detected in
the HCT116 culture at 5 days post-infection. In the case of PANC-
1, the presence of 100 mM ACV resulted in no virus being recov-
ered. As expected, virus was not recovered from the ‘no-cell’
control experiment after 5 days, owing to its instability at 37°C.
At 7 days post-infection, the amount of recovered virus was
reduced in every case. No virus was detected in the HCT116
cultures, which remained green confirming persistence of EGFP
expression. The presence of ACV prevented any virus being
recovered from the PANC-1 cultures. Even in its absence only
2 gfu ml–1 were detected. Lesser amounts of virus could still
be recovered from the MIAPACA and SW480 cultures, but the
presence of 100 mM ACV reduced this to very low levels in
MIAPACA (2 gfu ml–1) and to zero in SW480 cultures.
DISCUSSION
The use of a virus as an oncolytic agent for the treatment of
cancer is normally dependent on it being selectively replication-
competent in the tumour cell, to prevent the destruction of healthy
tissue. We are currently attempting to develop vectors for the treat-
ment of colorectal and pancreatic cancers based on HVS, a virus
which is known to be capable of infecting and persisting within
many different human cancer cell lines without apparently causing
CPE (Grassman and Fleckenstein, 1989; Simmer et al, 1991;
Stevenson et al, 1999). In this study, we have investigated the
interactions of an HVS vector expressing EGFP with cell lines
representative of the above disease targets. The virus was able to
efficiently infect all of the cell lines and, in three out of four
instances, stably infected lines were established in which all of the
cells expressed the marker protein EGFP. This finding was antici-
pated. However, surprisingly, the virus caused significant CPE and
cell death in the pancreatic cancer cell lines (MIAPACA and
PANC-1). This was so severe in the case of PANC-1 that the cell
sheet was completely destroyed. Extensive destruction of the
MIAPACA cells also occurred. In contrast, the colonic cancer cell
lines were apparently unaffected by the infection procedure and
exhibited no CPE.
In order to quantitatively assess the amount of virus, if any,
produced by these infected cultures, a virus recovery assay was
performed. The level of virus production after 5 days was greatest
in the pancreatic cell line MIAPACA. However, the destruction of
the PANC-1 monolayer at earlier times post-infection suggested
that significant virus production may well have occurred prior to
the 5-day sample. Unfortunately, as previously discussed, virus
production at early stages could not be distinguished from input
virus. According to control experiments, input virus was not
totally inactivated until 5 days post-infection. Considering the
relatively low levels of virus that were produced in any of the
cultures it seems possible that the CPE observed in the pancreatic
cell lines is not directly linked to the levels of virus production and
may instead be caused by the expression of a virus gene product to
which the cells are particularly sensitive. The expression of herpes
simplex virus type 1 immediate early genes, for example, is known
to cause CPE in a variety of human cells (Johnson et al 1994).
One of the advantages of using a herpesvirus-based vector in a
clinical setting is that replication of the virus can be controlled by
using the drug ACV (Elion, 1980). Our studies have shown that
ACV has activity against HVS and could therefore be used as a
safeguard in any future clinical investigation. In addition, ACV
appeared to accelerate the destruction of the PANC-1 culture. This
observation may be due to its activation in cells which were
expressing the HVS thymidine kinase gene product, thereby
contributing to the death of the cell. A similar phenomenon is
widely exploited by ‘suicide’ gene therapy strategies, involving
the use of the HSV-TK gene product (Culver et al, 1992).
In summary, we have shown that HVS appears to be selectively
cytopathic in pancreatic tumour cells. This unexpected result
suggests its possible application as an oncolytic agent for the treat-
ment of pancreatic cancer. If the virus, in its present replication-
competent form, was inoculated directly into a tumour it would be
unlikely to spread far from the injection site owing to the low
levels of virus production from infected human cells. We also note
that accidental inoculations into human subjects of the most
potently transforming strain of HVS have not resulted in sero-
conversion of the individuals involved or any recognizable disease
(Fleckenstein and Desrosiers, 1982). The strain of virus used in
these studies has already been attenuated, being incapable of
transforming any known cell type examined to date or causing
pathology in any animal model so far tested. HVS therefore merits
further evaluation with a view to possible exploitation of these
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Figure 2 Microscopic analysis of PANC-1 cells at 7 days post-infection
(A) mock-infected cells at 7 days post-infection (B) 7 days post-infection with
HVS-GFP at an moi of 1 using bright field microscopy
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Figure 3 Virus recovery assay. Numbers of green forming units per ml
(gfu ml–1) produced from the supernatants of infected MIAPACA, PANC-1,
SW480 and HCT116 cultures were determined on days 5 and 7
post-infection in the presence of different concentrations of acyclovir. The
supernatants were used to infect a permissive OMK cell line and gfu ml–1 is
an average taken from the results of two separate experimentsserendipitous findings for the treatment of this most intractable
malignancy.
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